热疗联合放化疗治疗局部晚期直肠癌疗效观察

目的 观察局部晚期直肠癌患者采用卡培他滨、放疗、热疗联合治疗的临床应用效果。方法 选取2015年2月—2019年2月本院收治的48例局部晚期直肠癌患者作为观察对象，根据不同治疗方案将患者分为联合组、对照组各24例。对照组采用卡培他滨、放疗治疗，联合组在对照组基础上联合热疗治疗。比较两组总有效率、T淋巴细胞亚群、不良反应发生率、复发率、转移率。病情达到完全缓解、部分缓解患者行手术治疗，记录两组手术率、无进展生存时间（PFS）。结果 联合组总有效率（87.50%）明显优于对照组（58.33%），有统计学意义（χ² = 5.1692，P < 0.05）；联合组不良反应发生率（12.50%）、复发率（4.17%）、转移率（8.33%）均低于对照组（45.83%）、（25.00%）、（33.33%），有统计学意义（χ² = 6.4538，4.1812，4.5474，P < 0.05）；联合组T淋巴细胞亚群各项指标水平均比对照组高（P < 0.05）；研究组手术率（83.33%）明显高于对照组（50.00%），有统计学意义（χ² = 6.0000，P < 0.05）；联合组PFS时间（56.2 ±5.2）月明显长于对照组（42.6 ±5.8）月，有统计学意义（t = 8.5531，P < 0.05）。结论 对局部晚期直肠癌患者采用卡培他滨、放疗、热疗联合治疗可优化整体治疗效果，增强机体免疫力，减少不良反应，防止肿瘤转移，近期疗效突出，手术率提高，PFS明显延长。

Effect of hyperthermia combined with chemoradiotherapy on locally advanced rectal cancer

Objective To observe the clinical effects of combined capecitabine, radiotherapy and hyperthermia in patients with locally advanced rectal cancer.Methods 48 patients with locally advanced rectal cancer admitted to our hospital from February 2015 to February 2019 were selected as observation subjects, and the patients were divided into 24 cases each in the combined group and control group according to different treatment plans. Both groups received capetabine and radiotherapy, and the combined group combined with hyperthermia.Comparing the overall efficiency, T-lymphocyte subpopulation, incidence of adverse events, relapse rate, and metastasis rate between the two groups.Patients with complete remission and partial remission underwent surgery recorded with the operation rate and progression free survival time for both groups.Results The overall effective rate of the combined group (87.50%) was statistically significantly better than that of the control group (58.33%) (χ² = 5.1692，P < 0.05); The incidence of adverse events (12.50%), recurrence (4.17%), and metastasis (8.33%) were statistically lower in the combined group than in the control group (45.83%), (25.00%), (33.33%) (χ² = 6.4538, 4.1812, 4.5474, P < 0.05); The subpopulations of T lymphocytes in the combined group had higher levels than those in the control group (P < 0.05). The operative rate (83.33%) in the combined group was significantly higher than that in the control group (50.00) (χ² = 6.0000, P < 0.05), and the PFS time (56.2 ±5.2 month) in the combined group was significantly longer than that in the control group (42.6 ±5.8 month) (t = 8.5531, P < 0.05).Conclusion For patients with locally advanced rectal cancer, the combination of capecitabine, radiotherapy and hyperthermia can optimize the overall therapeutic effect, enhance immunity, reduce adverse reactions, and prevent tumor metastasis, with prominent recent therapeutic effects, increased operation rate and significantly prolonged PFS.